Poster Abstracts (26th Annual)

The deadline to submit an abstract for poster presentations has passed.  To inquire about submitting a late-breaking abstract, please email amiyahira@pcf.org.

All PCF Retreat attendees are highly encouraged to submit an abstract for a poster presentation summarizing your recent prostate cancer research. All submitted abstracts will be publicly posted on the Retreat website and PCF Retreat mobile app. Due to space restrictions, a limited number of submissions will be selected to present posters at the meeting.


ABSTRACT SUBMISSION GUIDELINES

Please upload a Microsoft Word document containing your abstract on the Registration webpage.

The font must be in Tahoma, 10pt. Please make sure all formatting and special characters are displayed properly before submission. Failure to follow formatting guidelines may result in incorrect display of your abstract.

Abstracts must include: Title, Authors, Affiliations, Background, Methods, Results, Conclusions, and Conflict of Interest and Funding Acknowledgements.

Word limit is 450 words (abstract body).


POSTER PRESENTATION INFORMATION

Each poster must be a minimum of 36″ x 48″ and cannot exceed 48″ (vertical) x 96″ (horizontal). Poster board assignments and details on poster set-up will be emailed to presenters in early October.

The Poster Session will be held on Thursday, October 24, 2019, from 8:00pm to 10:30pm. Posters will be arranged in alphabetical order by the presenting author’s last name. Copies of the poster on 11″ x 17″ paper can accompany the poster as handouts but cannot be mounted on the poster boards.

For poster presentation inquiries please contact amiyahira@pcf.org or (310) 570-4705.


AuthorAbstract Title
Adelaiye-Ogala, RemiTargeting of the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting the induction of glucocorticoid receptor
Aggarwal, RahulResults from a Phase 1b/2a study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Akamatsu, ShusukeProspective evaluation of germline genetic testing in prostate cancer screening among Japanese.
Al Abo, MuthanaRace-related LMO7 exon skipping enhances prostate tumor invasion
Aldubayan, SaudLeveraging population-specific genomic architecture to dissect rare genetic drivers of PC heritability
Amend, SarahPolyploid giant cancer cells are actuators of therapeutic resistance and prostate cancer lethality
Armstrong, AndrewLiquid Biopsy Molecular Signatures of Hormone Therapy Resistance in Men with Metastatic CastrationResistant Prostate Cancer (mCRPC)
Asangani, IrfanCDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation
Asim, MohammadATM inhibition sensitises prostate cancer cells to PARP inhibitors
Augello, MichaelCHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis
Beshiri, MikeDifferentiation and subpopulation dynamics of treatment-emergent neuroendocrine prostate cancer in patient-derived organoids.
Bevan, CharlotteRole of bromodomain-containing androgen receptor cofactors in prostate cancer
Bjartell, AndersPIONEER: a BD4BO (Big data for better outcome) prostate cancer project
Bjartell, AndersHarnessing the power of big data in prostate cancer research – Data access and sources in the PIONEER project
Buelow, BenTNB-585: A Novel CD3xPSMA Bispecific Antibody for Efficient T Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release
Buskin, AdrianaTransforming precision medicine in lethal prostate cancer using stem cell derived organoids
Byrne, JamesExtremophile RNA delivery for Radioprotection in Prostate Cancer Patients
Cackowski, FrankA New Immune Competent, Androgen Receptor Positive Mouse Model of Prostate Cancer Bone Metastasis.
Calais, JeremieTotal-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients:
Potential Impact on bone scan guidelines
Calcinotto, AriannaThe role of microbiota in driving castration-resistant prostate cancer.
Campbell, DouglasProposed Study Design for a Miltuximab® Phase 1 Trial 89Zr/177Lu theranostic trial
Cantor, DiegoProstate Lesion Segmentation Using a Deep Learning Ensemble
Caram, MeganPatterns of Treatment Among Veterans with Advanced Prostate Cancer
Castro, ElenaImpact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Chakraborty, GoutamA Study on BRCA2-RB1 Co-loss, EMT and Aggressive Therapy Resistant Prostate Cancer
Chan, JuneFeasibility and acceptability of a web-based behavioral intervention in men with prostate cancer (PCa): a randomized pilot trial
Cheng, MichaelTumour lineage shapes BRCA-mediated phenotypes
Cherkasov, ArtemDevelopment of small molecule inhibitors targeting the N-terminal domain of human androgen receptor
Chou, JonathanClinical Outcomes in CDK12 Mutant Advanced Prostate Cancer
Chu, GinaMetastasis-initiating cells (MICs) recruit and reprogram bystander indolent cells to undergo lineage plasticity facilitating prostate cancer progression and metastasis
Coombs, CatherineImpact of clonal hematopoiesis mutations in solid tumor patients with a future focus for men with castration-resistant prostate cancer
Corey, EvaCRPC Tumors Are Inhibited by High Testosterone Therapy: Can We Identify Responders?
Cotter, KellieEpitranscriptomic Gene Regulation by N6-Adenosine-Methyltransferase in Prostate Cancer
Crawford, DavidNEXT GENERATION SEQUENCING OF MICROBIOMES IN POST-DRE URINE SAMPLES OF PROSTATE CANCER PATIENTS
Damayanti, NurTargeting androgen receptor phosphorylation to overcome enzalutamide resistance in advance prostate cancer
Davies, AlastairEpigenetic reprogramming of AR function underlies lineage infidelity in advanced prostate cancer
de Leeuw, ReneePhosphatase deregulation in prostate cancer progression
De Sarkar, NavoniliHRD Classification Framework for mCRPC: An Efficient Response Predictor for Precision Therapeutics Targeting DNA Repair Defect
Diaz-Meco, MariaMetabolic vulnerabilities in therapy resistance in prostate cancer
Dondossola, EleonoraRadium 223-mediates zonal cytotoxicity of prostate cancer in bone
Drake, JustinRET Kinase as a Driver of Neuroendocrine Prostate Cancer
Einstein, DavidIdentifying and Targeting Immunogenic Prostate Cancer at High Risk for Lethal Metastatic Progression
Flavell, RobertHyperpolarized interstitial pH imaging reveals grade dependent acidification in prostate cancer
Fletcher, ClaireMIR-346 INTERACTION WITH LONG NON-CODING RNA, NORAD, REVEALS A NOVEL GENOME PROTECTION MECHANISM AND MODULATES RESPONSE TO DNA-DAMAGING THERAPEUTICS IN ADVANCED PROSTATE CANCER
Gao, DongSingle-cell transcriptomics identifies a prostate luminal progenitor cell
Gao, DongERG orchestrates chromatin interactions driving prostate cell fate reprogramming
George, DanielFirst 500 Patients of IRONMAN: International Registry for Men with Advanced Prostate Cancer
Giacobbe, AriannaInvestigating the heterogeneity of circulating tumor cells in a mouse model of metastatic prostate cancer
Giancotti, FiliippoThe Polycomb Repressor Complex 1 Drives DoubleNegative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression
Gueron, GeraldineIntegrative tissue “omics” reveals a biomarker gene signature that re-defines prostate cancer risk for Gleason Score 6 & 7
Ha, GavinMulti-omic profiling of circulating tumor DNA in patients with CRPC
Hamid, AnisGenomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC)
Harmon, StephanieDeep Learning approach for classification of prostate cancer morphology features on whole mount digital pathology specimens
He, HoushengThe expression, function and clinical implication of circular RNAs in prostate cancer
Heaphy, ChristopherTelomere lengths differ significantly between small cell neuroendocrine carcinoma and adenocarcinoma of the prostate
Hebert-DeRouen, MindyNeighborhoods archetypes for understanding disparities in prostate cancer mortality
Hectors, StefanieLuminal water imaging of prostate cancer: quantitative comparison with diffusion-weighted imaging for characterization of cancer aggressiveness
Hua, JunjieRisk SNP-mediated bifunctional regulatory element drives prostate cancer through lncRNA PCAT19
Jamieson, ChristinaTargeting the WNT5A Receptor, ROR1, in Prostate Cancer
Jayaram, AnuradhaPlasma gene conversions after 1 cycle abiraterone acetate(AA) for metastatic castrationresistant prostate cancer (mCRPC): a biomarker analysis of a multi-centre, international trial
Jo, JanggunEvaluating Prostate Cancer by Functional Photoacoustic Imaging with Nanoprobe
Jones, JenniferDevelopment of a Pipeline for Analysis of Extracellular Vesicles in Health and Disease
Joshua, AnthonyThe effect of Metformin and Statin in Men with Biochemically Recurrent Prostate Cancer (BCRPC) – A single-centre retrospective study
Kaldjian, EricInvestigation of circulating tumor cells using RarePlex® Developer assays for custom biomarkers and validation of the RarePlex AR-V7 assay
Kaochar, SalmaTARGETING THE PI3K/Akt/mTOR/SREBP1 SIGNALING AXIS IN CASTRATION RESISTANT PROSTATE CANCER
Karthaus, WouterIdentifying novel regulators of lineage plasticity in an organoid model of transdifferentiation.
Kenfield, StaceyFeasibility of a remote-based exercise pilot randomized controlled trial in men with metastatic castration-resistant prostate cancer: research in progress from the CHAMP study
Kishan, AmarAssociation of Black Race with Improved Outcomes Following Definitive Radiotherapy with Androgen Deprivation Therapy in Localized Prostate Cancer: An Individual Patient Data Meta-Analysis of Eight Randomized Trials
Kregel, StevenA novel model of prostate cancer suggests enzalutamide functions through the immune system to diminish castration resistant and metastatic growth
Ku, Sheng-YuLoss of Notch signaling facilitates neuroendocrine differentiation in advanced prostate cancer
Kuhn, PeterGenomic Characterization of Circulating Tumor Cells in De Novo Metastatic Prostate Cancer
Labbe, DavidHigh-fat diet-dependent activation of the DNA damage response as an underlying mechanism of prostate cancer aggressiveness
Lack, NathanFunctional characterization of androgen receptor mediated transcription
Le Moigne, RonanEPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Leach, DamienThe role of the microenvironment in therapeutic response to anti-prostate cancer treatment.
Lee, JohnCUDC-907, a dual PI3K and HDAC inhibitor, with broad activity against castration-resistant prostate cancer
Lee, Wen-YeeUrinary Volatile Organic Compounds (VOCs) for the diagnosis of Prostate Cancer
Li, HuiInvestigating the Role of The Long Noncoding RNA SChLAP1-AS in Prostate Cancer Progression
Li, WenliangAndrogen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers
Liu, DeliImpact of distinct tumor lineage models on prostate cancer prognosis
Loeb, StacyQuality and Diversity of Information About Prostate Cancer Clinical Trials on YouTube
Lorenzin, FrancescaDependencies of CRPC cell fitness on ERG levels
Lu, XinMyeloid-Derived Suppressor Cells Inhibit T Cell Activation in Prostate Cancer through Nitrating LCK
Madan, RaviChemoImmunotherapy for the Treatment of Metastatic Prostate Cancer
Mahajan, KiranCIT kinase and HSPB8 as Novel Biomarkers for Identification of Metastatic Prostate Cancers
Mahajan, NupamA novel therapeutic agent (R)-9bMS for treatment of Castration Resistant Prostate Cancer
Mahal, BrandonProstate Cancer Outcomes and Genomic-Risk differences between African-American and White Men across Gleason Scores
Makarov, DanilThe Development and Implementation of the Prostate Cancer Imaging Stewardship (PCIS) Intervention
Markowski, MarkA Single Arm, Open Label Phase II trial of Bipolar Androgen Therapy in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC): A Comparison of Post-Abiraterone vs. PostEnzalutamide Patients. (RESTORE TRIAL)
Mateo, JoaquinDeveloping a tissue immunofluorescence-based assay to identify homologous recombination deficient prostate cancers towards patient stratification for treatment
Maxwell, KaraImplication of Gleason score for the precision medicine treatment of patients with localized prostate cancer
Mitsiades, NicholasK-11706 exerts potent anti-cancer activity via suppression of GATA2/AR/cMyc signaling axis in castration resistant prostate cancer
Miyamoto, DavidCirculating Tumor Cells and Ra-223 Response in Metastatic Castration-Resistant Prostate Cancer
Montie, HeatherAR acetylation modulates growth and viability of castrate-resistant prostate tumors
Morrissey, ColmRNA splicing factors SRRM3 and SRRM4 promote cellular plasticity in castration-resistant prostate cancer
Mouw, KentATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Preclinical Prostate Cancer Models
Mu, PingLoss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer
Mucci, LoreleiPatient Reported Outcomes Among Men with Advanced Prostate Cancer: Results from The IRONMAN Registry
Narayan, VivekInitial Dose-Escalation and Clinical Results from a Phase 1 Trial of PSMAredirected/TGFβ-insensitive CAR-T cells in Metastatic Castration-Resistant Prostate Cancer
Nickols, NicholasPhase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Non-Metastatic Prostate Cancer: Feasibility, Safety, and Translational Assessment of the Immune Environment of the Irradiated Prostates
Niknafs, YasharRetrospective analysis of the performance of MiPS in patients having had multi-parametric MRI
Oksala, RiikkaCYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer
Oh, DavidSingle cell discrimination of immunotherapy-induced changes in the prostate tumor microenvironment
Pachynski, RussellA PILOT TRIAL OF NEOANTIGEN DNA VACCINE IN COMBINATION WITH NIVOLUMAB/IPILIMUMAB AND PROSTVAC IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Patnaik, AkashSTING Activation to Overcome Resistance to Immune Checkpoint Blockade in PTEN-deficient Prostate Cancer
Perez-Lopez, RaquelMachine learning-based signature integrating radiomics and clinical data predicts response to immune checkpoint inhibitors in solid tumors.
Pilie, PatrickInhibitors of Ataxia-Telangiectasia Related (ATR) protein lead to innate immune pathway activation and enhanced response to immune therapy
Pippa, RaffaellaMechanistic study of the tumor suppressor role of MITF uncovers actionable translation targeting for prostate cancer.
Pitchiaya, SethuUnraveling molecular heterogeneities in advanced prostate cancer at single cell resolution
Posadas, EdwinThe NanoVelcro CTC-RNA assay: a new method for contemporary genomics and precision medicine via liquid biopsy
Qiao, YuanyuanTherapeutic targeting autophagy to sensitize cancer immunotherapy in prostate cancer
Quigley, DavidWhole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity
Reder, NicholasNon-destructive 3D pathology with open-top light-sheet microscopy
Reichert, ZacheryNon-invasive interrogation of oligometastatic castration-resistant prostate cancer and the benefit of metastasis directed therapy in the phase II FORCE randomized clinical trial
Rescigno, PasqualeImmunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Rodriguez-Bravo, VeronicaDissecting NUP-regulated pathways in aggressive prostate cancer.
Russo, JoshuaHER2-Mediated Mechanisms of Resistance to Androgen Deprivation Therapies in Advanced Castration-Resistant Prostate Cancer (CRPC)
Salami, SimpaDevelopment of a Whole-Urine, Next Generation Sequencing-Based Assay for Early Detection of Aggressive Prostate Cancer
Shafi, AyeshaPatient Derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response
Sharp, AdamClinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
Shelton, JeremyEstablishing a Prostate Cancer Data Core in VHA: Early Results
Shenderov, EugeneProfiling Anti-tumor Immunity in High-Risk Localized Prostate Cancer after Treatment Targeting the B7-H3 Checkpoint
Spratt, DanielTwo Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial
Stopsack, KonradAneuploidy drives lethal progression in prostate cancer
Stoyanova, TanyaTrop2 as a Novel Driver and Therapeutic Target for Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Phenotype
Strand, DouglasUrethral epithelia extend into the proximal prostate stem cell niche and are increased in prostate cancer
Stuart, JoshuaTranscriptional signatures provide alternative views of mCRPC pathological subtypes
Teplensky, MichelleRational Vaccinology for Prostate Cancer Using Spherical Nucleic Acids
Thaper, DakshDiscovery and characterization of first-in-field BRN2 inhibitors as a treatment strategy for Neuroendocrine Prostate Cancer
Ulmert, DavidGenetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
Vaishampayan, UlkaPhase II Trial of a Novel Immunotherapy Combination of Pembrolizumab and HER2Bi-armed Activated T Cells (BATS) in Metastatic Castrate Resistant Prostate Cancer
Vander Griend, DonaldMEIS-Mediated Suppression of Prostate Cancer Growth and Metastasis Through HOXB13- Dependent Regulation of Proteoglycans
VanderWeele, DavidOrganoid culture screen for combination therapies to target aggressive variant prostate cancer
Viswanathan, SrinivasFunctional genetic and genomic characterization of androgen receptor signaling in castration-resistant prostate cancer
Viswanathan, VasanthiTargeting the androgen-indifferent state of prostate cancer through ferroptosis induction
Wilkinson, ScottIntegrated radiologic, genomic and pathologic analysis revealed intratumoral divergent responses to neoadjuvant anti-androgen therapy
Wise, DavidA Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination with Docetaxel for the Treatment of Advanced Prostate Cancer with Elevated DKK1
Wu, AnjuiGenome-wide cfDNA analysis of metastatic prostate cancer
Wyatt, AlexanderDetection and characterization of mismatch repair defective metastatic prostate cancer using circulating tumour DNA
Yamaguchi, YukiModeling the human prostate tumor microenvironment to develop a novel chimeric antigen receptor T cell therapy
Yang, RendongComprehensive Analysis of Exitron Splicing in Human Cancer
Yunger, SharonTumor Infiltrating Lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy
Zhao, DiThe Cell–Extrinsic role of CHD1 in Prostate Cancer Development and Progression